NASDAQ: TAOXTao Synergies Inc Stock
$7.12-1.08 (-13.17%)
Updated Jul 9, 2025
TAOX Price
$7.12
Fair Value Price
N/A
Market Cap
$9.90M
52 Week Low
$1.84
52 Week High
$8.94
P/E
-0.71x
P/B
1.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.18M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.72
Operating Cash Flow
-$5M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TAOX Overview
Synaptogenix Incorporated is a biopharmaceutical company developing a product platform for the treatment of Alzheimer's based upon a drug candidate called Bryostatin-1. It is also assessing therapeutic applications of Bryostatin-1 for other neurodegenerative and cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-Pick Type C disease. Synaptogenix was incorporated in 2012 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TAOX's potential to beat the market
- TAOX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TAOX
RankedUnranked of 475
RankedUnranked of 475
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.60 | A | |
| $8.39 | A | |
| $44.07 | A |
Be the first to know about important TAOX news, forecast changes, insider trades & much more!
TAOX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TAOX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TAOX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TAOX is good value based on its book value relative to its share price (1.91x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
TAOX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TAOX due diligence checks available for Premium users.
Valuation
TAOX fair value
Fair Value of TAOX stock based on Discounted Cash Flow (DCF)
Price
$7.12
Fair Value
$14.31
Undervalued by
50.25%
TAOX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TAOX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.71x
Industry
-151.89x
Market
30.63x
TAOX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.91x
Industry
4.66x
TAOX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TAOX's financial health
Profit margin
Revenue
$0.0
Net Income
$385.2k
Profit Margin
0%
TAOX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$15.3M
Liabilities
$8.9M
Debt to equity
1.72
TAOX's short-term assets ($15.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TAOX's short-term assets ($15.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TAOX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
-$822.4k
TAOX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TAOX vs Biotech Stocks
Tao Synergies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.